Mersana Therapeutics Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
Mersana Therapeutics has a total shareholder equity of $8.4M and total debt of $25.4M, which brings its debt-to-equity ratio to 301.2%. Its total assets and total liabilities are $179.1M and $170.7M respectively.
Wichtige Informationen
301.2%
Verhältnis von Schulden zu Eigenkapital
US$25.38m
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | US$162.74m |
| Eigenkapital | US$8.43m |
| Gesamtverbindlichkeiten | US$170.70m |
| Gesamtvermögen | US$179.13m |
Jüngste Berichte zur Finanzlage
Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14
Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Recent updates
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade
Aug 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%
Aug 13Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues
Jun 19Mersana Therapeutics: On Hold While Waiting For Any Positive News
May 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Bain Capital discloses 4.8% stake in Mersana Therapeutics
Jan 13Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
Jan 11Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: MRSN's short term assets ($169.0M) exceed its short term liabilities ($62.2M).
Langfristige Verbindlichkeiten: MRSN's short term assets ($169.0M) exceed its long term liabilities ($108.5M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: MRSN has more cash than its total debt.
Schulden abbauen: MRSN's debt to equity ratio has increased from 4.4% to 301.2% over the past 5 years.
Bilanz
Liquiditätsreserve-Analyse
Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: MRSN has sufficient cash runway for more than a year based on its current free cash flow.
Vorhersage Cash Runway: MRSN has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 17.1% each year.